Biotech Tyra Biosciences lines up five investor events from Boston to Miami
Tyra Biosciences (NASDAQ: TYRA) announced its participation in five upcoming investor conferences between February 26 and March 12, 2026. These events include virtual and in-person presentations and one-on-one meetings in Boston and Miami. Webcasts and replays of the presentations will be available on the company's investor relations website.
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, a clinical-stage biotechnology company, announced its participation in five upcoming investor conferences between late February and mid-March 2026. The conferences include presentations and one-on-one meetings, providing the company an opportunity to discuss its precision medicine platform and pipeline, which focuses on FGFR biology. A live webcast of the presentations will be available on the company's investor relations website.
Price-Driven Insight from (TYRA) for Rule-Based Strategy
This article provides a price-driven analysis for Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models to generate trading strategies. It highlights a weak near-term sentiment but potential long-term strength, detailing specific entry, target, and stop-loss zones for position, momentum, and risk-hedging strategies. The analysis also includes multi-timeframe signal insights and risk-reward ratios for traders.
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
William Blair analyst Sami Corwin has maintained a "Buy" rating for TYRA BIOSCIENCES, INC. (TYRA.US). According to TipRanks, Corwin has a 52.7% success rate and an average return of 13.4% over the past year. TipRanks provides analysis data from third-party financial analysts, calculating average returns and success rates based on virtual portfolio performance.
Tyra Biosciences price target raised to $53 from $37 at Wedbush
Wedbush analyst Robert Driscoll raised the price target for Tyra Biosciences (TYRA) to $53 from $37, maintaining an Outperform rating. This increase follows positive Phase 3 data for BridgeBio's infigratinib, which validates FGFR3 inhibition for increasing height velocity in skeletal dysplasia patients. Wedbush believes this data is promising for Tyra Biosciences' dabogratinib, expecting significant improvements due to its selective FGFR3 inhibition.
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59
Barclays analyst Eliana Merle has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained a target price of $59. According to TipRanks data, Merle has a 43.3% success rate and a 4.9% average return over the past year. This report summarizes the analyst's stance based on independent third-party data provided by TipRanks.
Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch
Tyra Biosciences (TYRA) is progressing with its Phase 2 clinical trial (SURF302) for TYRA-300, an oral pill targeting FGFR3 altered low-grade bladder cancer. The study is evaluating the efficacy and safety of different doses, aiming to provide a non-invasive treatment option. Positive outcomes could significantly enhance the company's valuation and strategic position in the competitive oncology market.
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress
Tyra Biosciences (TYRA) is gaining investor attention following William Blair's coverage of its drug candidate dabogratinib, progress in its pipeline, and the start of a Phase 2 trial. Despite a recent slight pullback, Tyra's share price has seen significant returns over the last 90 days and year, leading to questions about whether its current Price-to-Book ratio of 5.6x, while below peers, is justified given its rich valuation compared to the broader biotech industry. The company, which currently reports no revenue and a net loss, faces inherent risks associated with clinical trials.
Wedbush Raises Price Target on Tyra Bioscience to $53 From $37, Keeps Outperform Rating
Wedbush has increased its price target for Tyra Bioscience to $53 from $37, while maintaining an "Outperform" rating on the stock. This adjustment reflects a more optimistic outlook by the analyst firm for the biotechnology company. The article also lists various other analyst actions and company news related to Tyra Biosciences over recent months.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts
Tyra Biosciences (NASDAQ:TYRA) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $37.17. Insider Robert J. More recently sold shares worth approximately $5.0 million, though he retains a significant stake, while institutional investors and hedge funds hold a majority of the company's stock. The company, which focuses on developing small-molecule therapies for genetically defined cancers, opened at $31.41, with a market cap of $1.68 billion and a negative P/E ratio of -16.80.
William Blair Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $59.62
William Blair analyst Sami Corwin has initiated coverage on TYRA BIOSCIENCES, INC. (TYRA.US) with a 'Buy' rating and set a target price of $59.62. Corwin has a 52.7% success rate and a 13.4% average return over the past year, according to TipRanks data. This information is for educational purposes and not an investment recommendation.
Tyra Biosciences stock hits 52-week high, reaching $31.0 By Investing.com
Tyra Biosciences (TYRA) stock has reached a 52-week high of $31.0, reflecting a 1-year return of 144.67% and a 6-month surge of 196.65%. The company, with a market capitalization of $1.65 billion and a strong balance sheet, is gaining investor confidence due to advancements in its drug development pipeline, including the initiation of a Phase 2 trial for dabogratinib. Analyst ratings are positive, with price targets as high as $59, and recent corporate appointments further strengthen the company's outlook.
Tyra Biosciences stock hits 52-week high, reaching $31.0
Tyra Biosciences Inc. (TYRA) stock has reached a 52-week high, climbing to $31.0, and has shown a significant 1-year return of 144.67%. This surge is attributed to investor confidence in its drug development pipeline and strategic partnerships, despite the company not yet being profitable. Analysts from Raymond James, Piper Sandler, and Wedbush have raised price targets, citing positive developments including a Phase 2 trial for dabogratinib and key executive appointments.
AlphaQuest LLC Has $421,000 Holdings in Tyra Biosciences, Inc. $TYRA
AlphaQuest LLC significantly reduced its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the third quarter, selling 43,013 shares and owning 30,060 shares valued at approximately $421,000. Despite this reduction, Wall Street analysts generally hold a "Moderate Buy" consensus rating for TYRA with an average target price of $37.17. Additionally, a director of the company, Robert J. More, sold a substantial number of shares in November, though corporate insiders collectively still maintain a 15.20% ownership of the stock.
(TYRA) Price Dynamics and Execution-Aware Positioning
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA) price dynamics, indicating weak near-term sentiment but potential for shifts in mid and long-term outlook. It presents institutional trading strategies, including long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis. The analysis highlights current support and resistance levels, emphasizing elevated downside risk in the long term.
Tyra Biosciences (TYRA) Price Target Increased by 24.36% to 42.58
The average one-year price target for Tyra Biosciences (NasdaqGS:TYRA) has been raised by 24.36% to $42.58 per share, up from the previous estimate of $34.24. This new target represents a 36.32% increase from the latest closing price of $31.24/share. Institutional ownership data shows a decrease in the number of funds holding TYRA, but an increase in their average portfolio weight dedicated to the stock.
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $50
Oppenheimer analyst Matthew Biegler has reiterated a Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and increased the target price from $36 to $50. According to TipRanks data, Biegler has a 41.7% success rate and an average return of 11.4% over the past year. This report highlights the analyst's continued confidence in TYRA BIOSCIENCES, INC.
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Promising 17% Upside Potential in Precision Medicine
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biotech company focused on precision medicine, particularly in FGFR biology, with a market capitalization of $1.73 billion. Analysts project a 17.12% upside potential, with an average target price of $37.88 and unanimous buy ratings, driven by its SNÅP platform and pipeline candidates like TYRA-300. Despite current unprofitability reflective of its R&D phase, the company's strong technical indicators and innovative approach in oncology and genetically defined conditions make it an attractive, albeit volatile, investment in the biotech sector.
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $59
Barclays has maintained its "Buy" rating for TYRA BIOSCIENCES, INC. (TYRA.US) and significantly increased its target price from $28 to $59. Analyst Eliana Merle, who has a 46.4% success rate and a 5.4% average return over the past year, made the adjustment. The analysis is based on data provided by TipRanks, an independent third party.
Barclays Initiates Coverage of Tyra Biosciences (TYRA) with Overweight Recommendation
Barclays has initiated coverage of Tyra Biosciences (TYRA) with an Overweight recommendation. Analysts project an average one-year price target of $34.24, suggesting a 10.28% upside from its current price. Institutional ownership in TYRA has seen a slight decrease in shares owned but an increase in average portfolio weight by existing funds, indicating a bullish outlook.
Tyra Biosciences stock hits all-time high of 31.58 USD By Investing.com
Tyra Biosciences (TYRA) stock has reached an all-time high of $31.58, marking a 103.12% increase over the past year, driven by investor confidence in its growth potential and innovative approaches. Market analysts have set a high price target of $42, supported by strong financials and a promising pipeline including dabogratinib. The company has also strengthened its leadership with key executive appointments.
Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month High - Should You Buy?
Tyra Biosciences (NASDAQ:TYRA) shares recently hit a new 52-week high of $32.08, trading up 4.1%. Analysts have issued a "Moderate Buy" consensus with a $36 price target, despite mixed ratings that include upgrades from Wedbush and Piper Sandler, and a downgrade from Wall Street Zen. The clinical-stage oncology firm reported in-line EPS last quarter and has significant institutional ownership, while insider selling was noted in November.
Tyra Biosciences stock hits all-time high of 31.58 USD By Investing.com
Tyra Biosciences stock climbed to an all-time high of $31.58, reflecting strong investor confidence and a 1-year increase of over 103%. The company's innovative approaches, strategic initiatives, and pipeline potential, particularly with lead asset dabogratinib, have contributed to this surge. Analysts have set a price target of $42, and recent leadership appointments are expected to further strengthen the company.
Tyra Biosciences stock hits all-time high of 31.58 USD
Tyra Biosciences Inc. has reached an all-time high stock price of $31.58 USD, marking a 103.12% increase over the past year. This surge is attributed to investor confidence in the biotech firm's growth potential and innovative approaches, with analysts setting a high price target of $42 USD. The company also recently saw leadership appointments and increased price targets from Piper Sandler, Wedbush, and Goldman Sachs, highlighting its lead asset dabogratinib and proprietary SNAP platform.
Assessing Tyra Biosciences (TYRA) Valuation After Piper Sandler Reaffirms Overweight On Dabogratinib Prospects
Piper Sandler has reaffirmed its "Overweight" rating on Tyra Biosciences (TYRA) due to the potential of its drug dabogratinib for FGFR3-driven conditions, with key data readouts expected in 2026. Despite a recent surge in share price, the company's valuation, reflected by a P/B ratio of 5.7x, is considered about right when compared to its peers, although it remains higher than the broader US Biotechs industry average. Investors are advised to consider the clinical and regulatory uncertainties and ongoing losses associated with Tyra's pipeline.
(TYRA) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting strong sentiment across all horizons and presenting three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It details entry and exit zones, target prices, and stop losses for various risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Tyra Biosciences (TYRA) Stock Report: Biotechnology Innovator with an 8.61% Upside Potential
Tyra Biosciences is a clinical-stage biotechnology company focusing on precision medicine for oncology and genetically defined conditions. The company's stock currently trades at the upper end of its 52-week range, reflecting market confidence despite negative earnings. Analysts show strong support with an average target price suggesting an 8.61% upside, though technical indicators point to potential near-term volatility.
Tyra Biosciences (NASDAQ:TYRA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Tyra Biosciences (NASDAQ:TYRA) from "hold" to "sell," despite other analysts like Wedbush and Piper Sandler raising their price targets, resulting in a "Moderate Buy" average rating from MarketBeat with a $36 target. The stock is currently trading near its 12-month high, with a market cap of $1.62 billion. Recent insider activity includes a director selling 10,000 shares, while institutional ownership stands at over 84%.
Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.1% - What's Next?
Shares of Tyra Biosciences (NASDAQ:TYRA) fell 5.1% during Friday's mid-day trading, with volume significantly lower than average. Despite the dip, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $36.00, following several increased price objectives from firms like Wedbush and Piper Sandler. Tyra Biosciences is a clinical-stage oncology company with a $1.58 billion market cap, negative earnings, and significant institutional ownership.
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price
Piper Sandler has increased its price target for Tyra Biosciences (NASDAQ:TYRA) to $42 from $33, maintaining an "overweight" rating and suggesting a potential upside of 35.88%. While analyst coverage is mixed, the average rating is a "Moderate Buy" with an average target of $36. The stock opened at $30.91, and institutional investors hold a significant 84.1% stake in the company.
Tyra Biosciences stock hits 52-week high at 30.85 USD By Investing.com
Tyra Biosciences Inc. (TYRA) stock has reached a 52-week high of $30.85, reflecting a 92.46% increase over the past year and strong investor confidence. Analysts maintain a "Strong Buy" recommendation with a target of $37, supported by the company's robust balance sheet and recent strategic developments, including raised price targets from Wedbush and new leadership appointments. The company is anticipated to have a busy 2026 with upcoming Phase 2 study data and continues to focus on developing precision medicines through its proprietary SNAP platform.
Tyra Biosciences stock hits 52-week high at 30.85 USD
Tyra Biosciences Inc. (TYRA) has reached a 52-week high of $30.85, reflecting a 92.46% increase in value over the past year due to strong investor confidence and positive performance in the biotechnology sector. The company shows financial health with more cash than debt and a high current ratio, leading analysts to a "Strong Buy" recommendation with a $37 price target. Recent developments include a raised price target from Wedbush, new coverage from Goldman Sachs, and strategic leadership appointments, all pointing to a positive growth trajectory.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Tyra Biosciences (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from six brokerages, with an average 1-year price target of $34.20. The company's stock opened at $28.77, with a market cap of $1.54 billion and a negative P/E ratio. Insider selling activity, with Director Robert J. More selling over 246,000 shares, and significant institutional and hedge fund ownership are also highlighted.
Tyra Biosciences (TYRA) Is Up 9.4% After New COO Hire And 52-Week High Has The Bull Case Changed?
Tyra Biosciences recently reached a 52-week high after hiring a new COO and Chief Regulatory Officer, strengthening its leadership for clinical-stage biotechnology programs. Despite this, the company faces risks including current unprofitability and dependence on its FGFR3-focused pipeline, particularly the success of its two ongoing Phase 2 studies. While the new executives might improve execution efficiency, the stock's potential overvaluation and long-term financial uncertainty remain key concerns for investors.
Tyra Biosciences stock hits 52-week high at $30.27
Tyra Biosciences Inc. has reached a new 52-week high of $30.27, representing a significant 89.17% appreciation over the past year and trading just under its peak of $30.39. The company, which specializes in cancer therapies, has a market cap of $1.61 billion and has seen a 204% return in the last six months, driven by investor confidence and its innovative pipeline. Recent positive developments include an increased price target from Wedbush to $37, new coverage from Goldman Sachs, and strategic appointments to its leadership team.
Tyra Biosciences stock hits 52-week high at $30.27 By Investing.com
Tyra Biosciences Inc. stock has reached a new 52-week high of $30.27, reflecting a significant increase of 369% from its 52-week low and an 89.17% appreciation over the past year. This milestone is supported by a strong market capitalization of $1.61 billion and recent positive analyst ratings from Wedbush and Goldman Sachs, who highlight the company's robust pipeline and proprietary SNAP platform. The company has also strengthened its leadership team with new COO and CCO appointments to further advance its clinical-stage biotechnology initiatives.
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $32
BofA Securities analyst Jason Zemansky has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and increased the price target from $28 to $32. According to TipRanks data, Zemansky has a 61.1% success rate and an average return of 21.2% over the past year. This report provides an update on analyst sentiment and target price adjustments for TYRA.
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6% - What's Next?
Tyra Biosciences (NASDAQ:TYRA) saw its shares drop 6% on Monday, trading with lower-than-average volume. Despite this dip, analysts generally maintain a "Moderate Buy" rating with an average price target of $33.17, following notable upgrades from Oppenheimer and Wedbush. Insider selling by Director Robert J. More was reported in November, but institutional ownership remains high at 84.14%.
Tyra Biosciences stock hits 52-week high at $26.36
Tyra Biosciences (TYRA) stock has reached a new 52-week high of $26.36, representing an 89.35% increase over the past year. The biopharmaceutical company, with a market capitalization of $1.36 billion, is focused on developing cancer therapies. Despite its strong financial health, InvestingPro suggests the stock may be overbought and trading above its Fair Value, though analysts like Wedbush and Goldman Sachs remain optimistic about its pipeline and platform.
Tyra Biosciences (NASDAQ:TYRA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Tyra Biosciences (NASDAQ:TYRA) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus based on mixed analyst coverage. The company's stock trades at $26.79 with a market cap of $1.43 billion, and insiders own 15.20% while institutional investors hold 84.14%. Recent insider activity shows a director selling a significant number of shares, reducing their stake.
(TYRA) Movement as an Input in Quant Signal Sets
This article provides an in-depth quantitative analysis of Tyra Biosciences Inc. (NASDAQ: TYRA) as of January 3, 2026. It highlights strong sentiment across all horizons, supporting an overweight bias despite identifying no clear price positioning signal and elevated downside risk. The analysis includes AI-generated trading strategies for different risk profiles and a multi-timeframe signal analysis with key support and resistance levels.
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a 25% Upside Potential in the Biotech Space
Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, shows a promising 25% upside potential with an average target price of $33.00, driven by its innovative SNÅP platform and pipeline candidates like TYRA-300. Despite strong analyst sentiment and bullish technical indicators, the company faces financial challenges common to early-stage biotech firms, including negative EPS and free cash flow, indicating a speculative investment with high risk appetite.
Tyra Biosciences stock hits 52-week high at $26.36 By Investing.com
Tyra Biosciences Inc. (TYRA) has reached a new 52-week high of $26.36, reflecting an 89.35% increase over the past year and a market capitalization of $1.36 billion. This growth is fueled by investor optimism, advancements in its drug development pipeline for cancer therapies, and positive analyst ratings, although InvestingPro data suggests the stock may be overbought. The company also announced key leadership appointments and awaits data from Phase 2 studies in 2026.
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year High - Time to Buy?
Tyra Biosciences (NASDAQ:TYRA) recently reached a new 52-week high of $26.35, trading at $26.275 with 125,611 shares exchanged. Analyst sentiment is mixed but leans positive with a "Moderate Buy" consensus and an average price target of $33.17, despite some sell downgrades. Insider transactions show a director selling 246,871 shares in November, while institutions own a significant portion of the stock.
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $37
Wedbush analyst Robert Driscoll has reiterated a "Buy" rating for TYRA BIOSCIENCES, INC. (TYRA.US) and increased the target price from $28 to $37. According to TipRanks, the analyst has a 40.0% success rate and a 3.0% average return over the past year. This adjustment reflects continued confidence in the biotechnology company.
Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires and Biotechnology Index Inclusion
Tyra Biosciences (TYRA) has gained significant attention after its inclusion in the S&P Biotechnology Select Industry Index and new leadership hires, leading to substantial share price returns. The company's valuation, currently at 5x book value, is assessed as "about right" when compared to a hand-picked peer group but expensive against the broader US biotech industry. The article questions whether these high expectations for future growth are fully priced in, particularly given the company currently has no revenue.
Tyra Biosciences (NASDAQ:TYRA) Reaches New 52-Week High - Here's What Happened
Tyra Biosciences (NASDAQ:TYRA) experienced a new 52-week high, trading as high as $26.34, with a significant volume of shares changing hands. The stock holds a consensus "Moderate Buy" rating with a target price of $33.17 from analysts. Insider activity shows a director reducing their stake, while institutional investors hold a substantial portion of the company's stock.
Does Tyra Biosciences (TYRA) Index Inclusion Mark a Turning Point in Its Institutional Story?
Tyra Biosciences (TYRA) was added to the S&P Biotechnology Select Industry Index on December 13, 2025, increasing its visibility and liquidity. While this inclusion and a director's planned share sale indicate growing institutional interest, the company currently has no revenue, rising losses, and its future relies on clinical, regulatory, and partnering outcomes. Investors should consider the inherent uncertainties and funding needs for its expanding pipeline, despite a potential fair value of $15.00 per share.
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
Robert J. More, a Director at Tyra Biosciences, sold 246,871 shares valued at $5 million as part of a pre-scheduled trading plan in November. Despite the sale, More retains a significant stake of nearly 4 million shares, worth approximately $77.6 million, and the biotech company's stock has rallied over 80% year-to-date. Tyra Biosciences, which focuses on precision oncology and rare genetic diseases, is in early stages of development and not yet generating revenue, indicating it's a risky investment despite analyst "buy" ratings.
(TYRA) Volatility Zones as Tactical Triggers
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting strong sentiment across all horizons supporting an overweight bias, despite elevated downside risk and no clear price positioning signal. It presents three AI-generated trading strategies—Position, Momentum, and Risk Hedging—with specific entry, target, and stop-loss zones, along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.
